Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting
JINAN,China,Dec. 25,2024-- During the 66th Annual Meeting of the American Society of Hematology (ASH) held in San Diego from December 7 to 10,preliminary results from the first human trial of QLS3201